
The FDA has approved Eli Lilly and Boehringer Ingelheim’s long-acting insulin Basaglar (insulin glargine injection – a biosimilar to rival Sanofi’s …

Lilly and Boehringer Ingelheim have launched their biosimilar insulin, called abasaglar, for the UK market. Abasaglar will now challenge the …
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion

